SUR10,High-quality dried freeze-dried peptide powder Semaglutide for fitness and weight loss
TDS 6 Inquiries
2805997-46-8
Pharmaceutical Grade
99.976%
SHENZHEN
Henghong Biotechnology
10mg*10vials/box
2026-11-05
Tirzepatide,Retatrutide,GHK-CU,KPV,MOTS-C,KLOW80
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionCertificates
-
TDS
Basic Info-
Product Name:
Survodutide
Other Name:Survodutide;BI 456906;Survodutide Peptide;Survodutide(BI 456906) 10MG;Survodutide acetate;Suvorouti;Swertide peptide;Suvodutide
CAS No.:2805997-46-8
Molecular Weight:0
EC Number:997-146-8
Color/Form:White to off-white
Categories:
Research-
Class:
GLP-1R agonist
Status:FDA-approved (Ozempic / Wegovy / Rybelsus)
Mechanism:Long-acting, selective glucagon-like peptide-1 (GLP-1) receptor agonist with 94% sequence homology to human GLP-1. Engineered for extended half-life (~1 week) via albumin binding (fatty acid acylation at Lys26) and resistance to DPP-4 degradation (Aib substitution at position 8). Promotes insulin secretion, inhibits glucagon release, delays gastric emptying, and reduces appetite via central nervous system GLP-1R activation.
Activity note:Potent, selective GLP-1R agonist. Reported binding affinity Ki = 0.38 ± 0.06 nM. Semaglutide is a human GLP-1 analog with structural modifications for albumin binding (C18 fatty diacid at Lys26) and enzymatic stability (Aib8 substitution).
Source:Lau J, et al. J Med Chem. 2015;58(18):7370-7380. Wilding JPH, et al. N Engl J Med. 2021;384(11):989-1002.DOI
Clinical Development:FDA:Ozempic, Wegovy, Rybelsus (approved 2017-12-05)
References-
ChEMBL:DrugBank:KEGG DRUG:PubChem:Literature:
NEJM: Wilding et al. (2021) — STEP-1; NEJM: Marso et al. (2016) — SUSTAIN-6; J Med Chem: Lau et al. (2015) — Discovery of Semaglutide; FDA: Ozempic (NDA 209637)
Disclaimer:Semaglutide is approved as a prescription medicine (Ozempic, Wegovy, Rybelsus) in certain jurisdictions. This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Tirzepatide,Retatrutide,GHK-CU,KPV,MOTS-C,KLOW80
-
Location:
2nd Floor, Room 0996, No. 963 Tianyuan Road, Tianhe District, Guangzhou
-
Average lead Time:
5
-
Total Annual Revenue:
Less than $1 million
-
Total Employees:
51-100
-
Year of Establishment:
2026
-
-
Inquiry History6 Inquiries
Country Product Purchase Quantity Date Posted
United States
Survodutide cas 2805997-46-8
2 MT Nov 14, 2025
United States
Survodutide
10 MG Oct 7, 2024
United States
Survodutide 10MG
10 MG Nov 17, 2025
Ecuador
Survodutide
10 MG Jun 17, 2026
United States
urvodutide
10 G Aug 10, 2025
Bangladesh
Survodutide
1 KG Jul 3, 2024 Post an enquiry for this product